Therapeutic Targets and Treatment Improvement Through Key Oncogenic Pathways in Cancer
DOI:
https://doi.org/10.56294/saludcyt20251581Keywords:
Oncogenic Pathways, Targeted Therapy, Cancer Treatment, Precision Medicine, Treatment Resistance, Molecular ProfilingAbstract
Many treatments for cancer have limited effectiveness and serious side effects, but it is still one of the main reasons of illness and death around the world. Because DNA abnormalities and the misregulation of signaling pathways make cancer so complicated, we need to find new therapy targets so that we can make medicines that work better and are more tailored to each person. Important cancer-causing pathways, including the PI3K/AKT/mTOR, MAPK/ERK, Wnt/β-catenin, and JAK/STAT pathways, help cells grow, survive, form new blood vessels, and hide from the immune system. Understanding the molecular processes that control these pathways has made it possible to create tailored treatments that stop the abnormal signals that cause cancer to spread. This study looks at the current state of therapeutic targets and how key tumor pathways are used to treat cancer. New tailored therapies, like small chemicals, monoclonal antibodies, and immune checkpoint inhibitors, have shown promise in both clinical studies and everyday use. Resistance to these medicines, on the other hand, is still a big problem. Resistance mechanisms, like changes in the target gene, the start of alternative pathways, or immune escape, make treatment results more difficult and need more research. Combining genetic analysis and precision medicine makes it possible to find changes that are unique to cancer. This makes it easier to create personalized therapies that are better at beating treatment resistance. Using focused medicines along with standard treatments like radiation and chemotherapy is a new way to improve treatment effectiveness and reduce resistance.
References
[1] Arora, T.; Mullangi, S.; Lekkala, M.R. Ovarian Cancer. In StatPearls; StatPearls Publishing LLC.: Treasure Island, FL, USA, 2023.
[2] Charkhchi, P.; Cybulski, C.; Gronwald, J.; Wong, F.O.; Narod, S.A.; Akbari, M.R. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers 2020, 12, 3730.
[3] Richardson, D.L.; Eskander, R.N.; O’Malley, D.M. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance: A Narrative Review. JAMA Oncol. 2023, 9, 851–859.
[4] Veneziani, A.C.; Gonzalez-Ochoa, E.; Alqaisi, H.; Madariaga, A.; Bhat, G.; Rouzbahman, M.; Sneha, S.; Oza, A.M. Heterogeneity and treatment landscape of ovarian carcinoma. Nat. Rev. Clin. Oncol. 2023, 20, 820–842.
[5] Reid, B.M.; Permuth, J.B.; Sellers, T.A. Epidemiology of ovarian cancer: A review. Cancer Biol. Med. 2017, 14, 9–32.
[6] Momenimovahed, Z.; Tiznobaik, A.; Taheri, S.; Salehiniya, H. Ovarian cancer in the world: Epidemiology and risk factors. Int. J. Women’s Health 2019, 11, 287–299.
[7] Kinnear, H.M.; Tomaszewski, C.E.; Chang, F.L.; Moravek, M.B.; Xu, M.; Padmanabhan, V.; Shikanov, A. The ovarian stroma as a new frontier. Reproduction 2020, 160, R25–R39.
[8] Lukanović, D.; Kobal, B.; Černe, K. Ovarian Cancer: Treatment and Resistance to Pharmacotherapy. Reprod. Med. 2022, 3, 127–140.
[9] Lino-Silva, L.S. Ovarian carcinoma: Pathology review with an emphasis in their molecular characteristics. Chin. Clin. Oncol. 2020, 9, 45.
[10] Yang, J.; Huang, S.; Cheng, S.; Jin, Y.; Zhang, N.; Wang, Y. Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities. Front. Cell Dev. Biol. 2021, 9, 701429.
[11] Babaier, A.; Mal, H.; Alselwi, W.; Ghatage, P. Low-Grade Serous Carcinoma of the Ovary: The Current Status. Diagnostics 2022, 12, 458.
[12] Wang, Y.; Hong, S.; Mu, J.; Wang, Y.; Lea, J.; Kong, B.; Zheng, W. Tubal Origin of “Ovarian” Low-Grade Serous Carcinoma: A Gene Expression Profile Study. J. Oncol. 2019, 2019, 8659754.
[13] Van Nieuwenhuysen, E.; Busschaert, P.; Laenen, A.; Moerman, P.; Han, S.N.; Neven, P.; Lambrechts, D.; Vergote, I. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. Neoplasia 2019, 21, 582–590.
[14] Cheasley, D.; Nigam, A.; Zethoven, M.; Hunter, S.; Etemadmoghadam, D.; Semple, T.; Allan, P.; Carey, M.S.; Fernandez, M.L.; Dawson, A.; et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J. Pathol. 2021, 253, 41–54.
[15] Roldán-Romero, J.M.; Valdivia, C.; Santos, M.; Lanillos, J.; Maroto, P.; Anguera, G.; Calsina, B.; Martinez-Montes, A.; Monteagudo, M.; Mellid, S.; et al. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. Int. J. Cancer 2023, 153, 1300–1312.
[16] Di Lorenzo, P.; Conteduca, V.; Scarpi, E.; Adorni, M.; Multinu, F.; Garbi, A.; Betella, I.; Grassi, T.; Bianchi, T.; Di Martino, G.; et al. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers. Front. Oncol. 2022, 12, 970918.
[17] Morand, S.; Devanaboyina, M.; Staats, H.; Stanbery, L.; Nemunaitis, J. Ovarian Cancer Immunotherapy and Personalized Medicine. Int. J. Mol. Sci. 2021, 22, 6532.
[18] Marks, Z.R.C.; Campbell, N.K.; Mangan, N.E.; Vandenberg, C.J.; Gearing, L.J.; Matthews, A.Y.; Gould, J.A.; Tate, M.D.; Wray-McCann, G.; Ying, L.; et al. Interferon-ε is a tumour suppressor and restricts ovarian cancer. Nature 2023, 620, 1063–1070.
[19] Gasparri, M.L.; Bardhi, E.; Ruscito, I.; Papadia, A.; Farooqi, A.A.; Marchetti, C.; Bogani, G.; Ceccacci, I.; Mueller, M.D.; Benedetti Panici, P. PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track? Geburtshilfe Frauenheilkd. 2017, 77, 1095–1103.
[20] Vergote, I.; Gonzalez-Martin, A.; Lorusso, D.; Gourley, C.; Mirza, M.R.; Kurtz, J.-E.; Okamoto, A.; Moore, K.; Kridelka, F.; McNeish, I.; et al. Clinical research in ovarian cancer: Consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2022, 23, e374–e384.
[21] O’Malley, D.M.; Krivak, T.C.; Kabil, N.; Munley, J.; Moore, K.N. PARP Inhibitors in Ovarian Cancer: A Review. Target. Oncol. 2023, 18, 471–503.
[22] Kurnit, K.C.; Fleming, G.F.; Lengyel, E. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstet. Gynecol. 2021, 137, 108–121.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Adya Kinkar Panda, Reddy B, Amit Kumar, Kamineni Sairam, Anand Gudur, Sangeetha M (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
